About 4 results found for searched term "Dxd" (0.243 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13744 | Dxd | Topoisomerase |
| Exatecan derivative for ADC | ||
| Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a). | ||
| M25010 | Patritumab deruxtecan | Drug-Linker Conjugates for ADC |
| HER3-DXd; U3-1287; U3-1402 | ||
| Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. | ||
| M40765 | Datopotamab deruxtecan | Others |
| Dato-DXd | ||
| Datopotamab deruxtecan is an antibody-coupled drug (ADC) consisting of a humanized, monoclonal antibody targeting human trophoblast cell surface glycoprotein antigen 2 (Trop2) conjugated to an innovative DNA topoisomerase I inhibitor (DXd) for use in studies related to non-small cell lung cancer (NSCLC). | ||
| M10396 | Deruxtecan | Drug-Linker Conjugates for ADC |
| Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
